Die Wertigkeit der Fluordeoxyglukose Positronenemissionstomographie (FDG-PET) in der Diagnostik von Pankreasprozessen

Zusammenfassung

In der onkologischen Diagnostik nutzt das funktionsbildgebende Verfahren der Positronenemissionstomographie mit F-18-Fluorodeoxyglukose (FDG-PET) den zumeist erhöhten Zuckerstoffwechsel bei malignen Prozessen im Vergleich zu nicht maligne verändertem Gewebe. Diese kurze Übersicht beschreibt die Grundlagen der FDG-PET und gibt einen Überblick über die Wertigkeit in der Diagnostik von Pankreasprozessen. Die Sicherheit in der Differenzierung von entzündlichen Prozessen und dem Pankreaskarzinom kann durch eine dynamische Akquisition der Pankreasläsion erhöht werden.

Abstract

Fluorine-18 fluordeoxyglucose positron emission tomography (FDG-PET) is a functional imaging modality that is based on the metabolic activity wich is higher in most malignant tumors than benign tissues. This short review describes the basics of FDG-PET and gives a discussion of its role in differentiation of focal pancreatic lesions. The diagnostic accuracy in patients with active inflammation or cancer of the pancreas can be improved by dynamic acquisition of focal pancreatic lesions.

FDG-PET - Positronenemissionstomographie - Pankreaskarzinom

FDG-PET - Positron emission tomography - Pancreatic cancer - Glucose metabolism

Literatur

• 1 Bakkevold K E, Kambestad B. Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater - the prognostic factors influencing the long-term results. A prospective multicentre study.  Eur J Surg Oncol. 1993;  19 (2) 147-161
• 2 Bares R, Dohmen B M, Cremerius U, Fass J, Teusch M, Büll U. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].  Radiologe. 1996;  36 (5) 435-440
• 3 Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, Schumpelick V, Mittermayer C, Büll U. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer.  Radiology. 1994;  192 (1) 79-86
• 4 Delbeke D, Rose D M, Chapman W C, Pinson C W, Wright J K, Beauchamp R D, Shyr Y, Leach S D. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.  J Nucl Med. 1999;  40 (11) 1784-1791
• 5 Diederichs C G, Staib L, Glatting G, Beger H G, Reske S N. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies.  J Nucl Med. 1998;  39 (6) 1030-1033
• 6 Diederichs C G, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs H J, Beger H G, Reske S N. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.  Pancreas. 2000;  20 (2) 109-116
• 7 Engel H, Steinert H, Buck A, Berthold T, Huch Boni R A, von Schulthess G K. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations.  J Nucl Med. 1996;  37 (3) 441-446
• 8 Friess H, Langhans J, Ebert M, Beger H G, Stollfuss J, Reske S N, Buchler M W. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography.  Gut. 1995;  36 (5) 771-777
• 9 Fröhlich A, Diederichs C G, Staib L, Vogel J, Beger H G, Reske S N. Detection of liver metastases from pancreatic cancer using FDG PET.  J Nucl Med. 1999;  40 (2) 250-255
• 10 Haberkorn U, Ziegler S I, Oberdorfer F, Trojan H, Haag D, Peschke P, Berger M R, Altmann A, van Kaick G. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models.  Nucl Med Biol. 1994;  21 (6) 827-834
• 11 Ho C L, Dehdashti F, Griffeth L K, Buse P E, Balfe D M, Siegel B A. FDG-PET evaluation of indeterminate pancreatic masses.  J Comput Assist Tomogr. 1996;  20 (3) 363-369
• 12 Hoh C K, Hawkins R A, Glaspy J A, Dahlbom M, Tse N Y, Hoffman E J, Schiepers C, Choi Y, Rege S, Nitzsche E. et al . Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.  J Comput Assist Tomogr. 1993;  17 (4) 582-589
• 13 Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, Kajiyama T, Ohshio G, Imamura M, Konishi J. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.  Radiology. 1995;  195 (2) 345-352
• 14 Jadvar H, Fischman A J. Evaluation of pancreatic carcinoma with FDG PET.  Abdom Imaging. 2001;  26 (3) 254-259
• 15 Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, Isomura T, Ito S, Nishino M, Ishigaki T. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.  Eur J Nucl Med. 1995;  22 (1) 32-39
• 16 Keogan M T, Tyler D, Clark L, Branch M S, McDermott V G, DeLong D M, Coleman R E. Diagnosis of pancreatic carcinoma: role of FDG PET.  AJR Am J Roentgenol. 1998;  171 (6) 1565-1570
• 17 Klever P, Bares R, Fass J, Büll U, Schumpelick V. PET with fluorine-18 deoxyglucose for pancreatic disease.  Lancet. 1992;  340 (8828) 1158-1159
• 18 Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, Hosotani R, Imamura M, Konishi J. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.  Cancer. 2000;  89 (12) 2547-2554
• 19 Nitzsche E U, Hoegerle S, Mix M, Brink I, Otte A, Moser E, Imdahl A. Non-invasive differentiation of pancreatic lesions: is analysis of FDG kinetics superior to semiquantitative uptake value analysis?.  Eur J Nucl Med Mol Imaging. 2002;  29 (2) 237-242
• 20 Reske S N, Grillenberger K G, Glatting G, Port M, Hildebrandt M, Gansauge F, Beger H G. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma.  J Nucl Med. 1997;  38 (9) 1344-1348
• 21 Reske S N, Kotzerke J. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, “Onko-PET III”, 21 July and 19 September 2000.  Eur J Nucl Med. 2001;  28 (11) 1707-1723
• 22 Schek N, Hall B L, Finn O J. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma.  Cancer Res. 1988;  48 (22) 6354-6359
• 23 Schober O, Lottes G. [Positron emission tomography and radiation exposure].  Nuklearmedizin. 1994;  33 (5) 174-177
• 24 Shreve P D. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease.  Eur J Nucl Med. 1998;  25 (3) 259-264
• 25 Stollfuss J C, Glatting G, Friess H, Kocher F, Berger H G, Reske S N. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.  Radiology. 1995;  195 (2) 339-344
• 26 van Gulik T M, Moojen T M, van Geenen R, Rauws E A, Obertop H, Gouma D J. Differential diagnosis of focal pancreatitis and pancreatic cancer.  Ann Oncol. 1999;  10 (Suppl 4) 85-88
• 27 Warburg O. On the origin of cancer cells. Science 1956; 123 - 309
• 28 Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, Klever P, Sabri O, Schumpelick V, Büll U. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases.  Eur J Nucl Med. 1997;  24 (6) 678-682